Arvinas to present Phase 1 biomarker data for ARV-102 Parkinson’s trial at 2026 MDS Congress

By Public Technologies
  • Arvinas scheduled late-breaking Phase 1 biomarker data for ARV-102 in Parkinson’s disease for presentation on Oct. 7, 2026.
  • Results have not been presented yet; the company flagged new oculomotor findings alongside biomarker readouts from the trial.
  • ARV-102 is an oral PROTAC designed to cross the blood-brain barrier and degrade LRRK2, a target linked to Parkinson’s disease.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arvinas Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610011601PRIMZONEFULLFEED9838018) on October 01, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk